Explore

Trendline Trendline
Silexion Therapeutics Advances Pancreatic Cancer RNA Drug to Clinical Trials

Silexion Therapeutics Advances Pancreatic Cancer RNA Drug to Clinical Trials

Silexion Therapeutics Advances Pancreatic Cancer RNA Drug to Clinical Trials
Trendline Trendline
Silexion Advances SIL204 with GMP Manufacturing and Phase 2/3 Trial Approval

Silexion Advances SIL204 with GMP Manufacturing and Phase 2/3 Trial Approval

Silexion Advances SIL204 with GMP Manufacturing and Phase 2/3 Trial Approval
Trendline Trendline
Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204
Trendline Trendline
Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials

Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials

Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials
Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer CAR-T Therapy Trial
Trendline Trendline
Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy
Reuters Reuters
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

By Deena Beasley and Nancy Lapid May 14 (Reuters) - U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a speedy FDA approval.
Trendline Trendline
AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform
Trendline Trendline
Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy
Trendline Trendline
Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026